Preventing colorectal cancer in patients with Lynch Syndrome using immune strategies
Cancer Immune-Interception for Lynch Syndrome
This study is looking at how we can use the body's immune system to help prevent colorectal cancer in people with Lynch Syndrome by finding specific markers from genetic changes and testing a medication called naproxen to boost immune responses in the colon.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10923965 on NIH RePORTER |
What this research studies
This research focuses on Lynch Syndrome, a hereditary condition that significantly increases the risk of colorectal cancer. It investigates how the immune system can be harnessed to prevent cancer in patients with this syndrome by identifying specific neoantigens that arise from genetic mutations. The study aims to enhance the immune response through the use of chemopreventive agents like naproxen, which may activate immune cells in the colorectal area. By analyzing genomic data from pre-cancerous lesions, the research seeks to develop targeted immune-interception strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Lynch Syndrome who are at high risk for developing colorectal cancer.
Not a fit: Patients without Lynch Syndrome or those who have already developed advanced colorectal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive treatments for colorectal cancer in individuals with Lynch Syndrome.
How similar studies have performed: Previous research has shown promise in using immune strategies for cancer prevention, particularly in genetically predisposed populations, indicating potential success for this approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Vilar Sanchez, Eduardo — University of Tx Md Anderson Can Ctr
- Study coordinator: Vilar Sanchez, Eduardo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.